Aeglea BioTherapeutics

3:15 PM - 3:30 PM, Tuesday, June 4, 2019 ・ Theater 3
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.
Ticker:
AGLE
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Pegzilarginase for Arginase I Deficiency
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
President and CEO
Aeglea BioTherapeutics